NCT07161258RecruitingPhase 2
A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
An Open-label, Single-arm Study to Evaluate Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
This open label, single arm study will evaluate the PK and PD effects of fenebrutinib in children and adolescents with RMS aged between 10 and \< 18 years. This study consists of a Dose Exploration Period and an Optional Extension Period. Eligible participants may choose to continue treatment with fenebrutinib in the optional extension period after completing the dose exploration period.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 20 Aug 2025
- Start date
- 6 Oct 2025
- Primary completion date
- 8 Jun 2027
- Lead sponsor
- Hoffmann-La Roche
- Diseases
- Multiple sclerosis
- NCT number
- NCT07161258
- EU CT number
- 2024-519800-28-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 12
- From 6 Oct 2025 to the primary completion date, 8 Jun 2027
- 17 sites in 7 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent or anticipated use of prohibited medications/treatments:
- Drugs interacting with fenebrutinib (Cytochrome P450 3A4 \[CYP3A4\] inhibitors)
- Any other investigational therapy, anticoagulants, certain vaccines
Other illness
- Co-morbid Conditions:
- Potentially confounding neurological, somatic, or metabolic disorders
- Current clinically significant psychiatric or medical illness
- History of cancer, transplants, or bleeding disorders
- Active, recurrent, or chronic infections
- Certain disease-modifying therapy (DMT) and other immunosuppressants
Lab values
- Abnormal liver function tests or blood counts
Other
- A diagnosis of primary progressive multiple sclerosis (PPMS) or non-active secondary progressive multiple sclerosis (SPMS)
- Inability to complete an MRI scan or get gadolinium
- Sensitivity or intolerance to any ingredient (including excipients) of fenebrutinib tablets
- A score of 4 or 5 on the "last 6 months" section of the screening SI section or "yes" on any item of the "last 6 months" Suicidal Behavior (SB) section of the C-SSRS or a positive answer on Question 9 of the Patient Health Questionnaire-9 Modified for Adolecents (PHQ-A) or significant risk of suicide, in the investigator's judgment
Who the study is looking for
- A diagnosis of RMS in accordance with the International Pediatric Multiple Sclerosis Study Group (IPMSSG) criteria for pediatric MS, Version 2012, and the revised 2017 McDonald Criteria and one or more of the following: at least one MS relapse during the previous year or two MS relapses in the previous 2 years or evidence of at least one Gd enhancing lesion on MRI within 6 month
- Expanded Disability Status Scale (EDSS) at screening from 0 to 5.5 points, inclusive
- Children and adolescents must have received all childhood vaccinations as per local/national recommendations for childhood vaccination against infectious diseases
Age in the registry: 10 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (17)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| INECO Neurociencias Oroño Coordinator of this site? Confirm its status | Rosario | Argentina | Recruiting |
| Sanatorio del Sur S.A. Coordinator of this site? Confirm its status | San Miguel de Tucumán | Argentina | Recruiting |
| L2IP - Instituto de Pesquisas Clínicas Ltda Coordinator of this site? Confirm its status | Brasília | Brazil | Recruiting |
| Instituto de Neurologia de Curitiba - Hospital Ecoville Coordinator of this site? Confirm its status | Curitiba | Brazil | Recruiting |
| Nucleo de Pesquisa Clinica do Rio Grande do Sul NPCR Coordinator of this site? Confirm its status | Porto Alegre | Brazil | Recruiting |
| Centro de Pesquisas Clinicas - CPCLIN Coordinator of this site? Confirm its status | São Paulo | Brazil | Recruiting |
| Hospital Universitario de la Princesa Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| Hospital Universitario Ramón y Cajal Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| Hospital Universitario Virgen Macarena Coordinator of this site? Confirm its status | Seville | Spain | Recruiting |
| Neurociencias Estudios Clinicos S.C. Coordinator of this site? Confirm its status | Culiacán | Mexico | Recruiting |
| Clinstile, S.A. de C.V. Coordinator of this site? Confirm its status | Mexico City | Mexico | Recruiting |
| Uniwersyteckie Centrum Kliniczne Coordinator of this site? Confirm its status | Gdansk | Poland | Recruiting |
| Uniwersytecki Szpital Kliniczny w Poznaniu Coordinator of this site? Confirm its status | Poznan | Poland | Recruiting |
| Instytut Pomnik Centrum Zdrowia Dziecka Coordinator of this site? Confirm its status | Warsaw | Poland | Recruiting |
| Centro Clnico Acadmico - Braga, Associao (2CA-Braga) Coordinator of this site? Confirm its status | Braga | Portugal | Recruiting |
| Unidade Local de Saúde de Coimbra, E.P.E. Coordinator of this site? Confirm its status | Coimbra | Portugal | Recruiting |
| UH of State NPC Danulo Halytsky NMU in Lviv CID, Clinic of Neurology and Neurosurgery Coordinator of this site? Confirm its status | Lviv | Ukraine | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.